Indices of oxidative stress in pregnancy with fetal growth restriction

Free Radical Research

Volumn 41, Issue 8, 2007, Pages 870-873

  Karowicz Bilinska, Agata ^a   Kȩdziora Kornatowska, Kornelia ^b   Bartosz, Grzegorz ^c,d  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY OF RZESZÓW   (Poland)

Author keywords

it; 1 antitrypsin; Arginine; Fetal growth restriction; Lipid peroxidation; Pregnancy; Total antioxidant capacity

Indexed keywords

ACARD; ACETYLSALICYLIC ACID; ALKENE DERIVATIVE; ALPHA 1 ANTITRYPSIN; ARGININE; MALONALDEHYDE; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETUS MORTALITY; HUMAN; INTRAUTERINE GROWTH RETARDATION; LIPID PEROXIDATION; OXIDATIVE STRESS; PREGNANCY COMPLICATION; PREMATURITY;

ADULT; ALPHA 1-ANTITRYPSIN; ARGININE; ASPIRIN; BIOLOGICAL MARKERS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; LIPID PEROXIDATION; MALONDIALDEHYDE; OXIDATIVE STRESS; PREGNANCY; SERUM;

EID: 34547538537     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760701291647     Document Type: Article

References (33)

1. Aucott, SW, Donohue, PK and Northington, FJ (2004) Increased morbidity in severe early intrauterine growth restriction. J Perinatol, 24, pp. 435-440.
2. Baschat, AA (2005) Arterial and venous Doppler in the diagnosis and management of early onset fetal growth restriction. Early Hum Dev, 81, pp. 877-887.
3. Sieroszewski, P., Suzin, J. and Karowicz-Bilinska, A. (2004) Ultrasound evaluation of intrauterine growth restriction therapy by a nitric oxide donor (-arginine). J Matern Fetal Neonatal Med, 15, pp. 363-366.
4. Takagi, Y., Nikaido, T., Toki, T., Kita, N., Kanai, M., Ashida, T., Ohira, S., Ohira, S. and Konishi, I. (2004) Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. Virchows Arch, 444, pp. 49-55.
5. Longini, M., Perrone, S., Kenanidis, A., Vezzosi, P., Marzocchi, B., Petraglia, F., Centini, G. and Buonocore, G. (2005) Isoprostanes in amniotic fluid: A predictive marker for fetal growth restriction in pregnancy. Free Radic Biol Med, 38, pp. 1537-1541.
6. Vosatka, RJ, Hassoun, PM and Harvey-Wilkes, KB (1998) Dietary -arginine prevents fetal growth restriction in rats. Am J Obstet Gynecol, 178, pp. 242-246.
7. Xiao, XM and Li, LP (2005) -Arginine treatment for asymmetric fetal growth restriction. Int J Gynaecol Obstet, 88, pp. 15-18.
8. Galao, AO, da Costa, BE Pinheiro, d'Avila, DO and de Figueiredo, CE Poli (2004) -Arginine erythrocyte transport increases during pregnancy and immediately postpartum. Am J Obstet Gynecol, 191, pp. 572-575.
9. da Costa, BP, Steibel, JP, Antonello, IC, Guimaraes, JA and de Figueiredo, CE Poli (2004) -Arginine erythrocyte transport in normal pregnant and preeclamptic women. Am J Obstet Gynecol, 190, pp. 468-471.
10. Rytlewski, K., Olszanecki, R., Lauterbach, R., Grzyb, A. and Basta, A. (2006) Effects of oral -arginine on the foetal condition and neonatal outcome in preeclampsia: A preliminary report. Basic Clin Pharmacol Toxicol, 99, pp. 146-152.
11. Chiueh, CC (1999) Neuroprotective properties of nitric oxide. Ann N Y Acad Sci, 890, pp. 301-311.
12. Mohanakumar, KP, Thomas, B., Sharma, SM, Muralikrishnan, D., Chowdhury, R. and Chiueh, CC (2002) Nitric oxide: An antioxidant and neuroprotector. Ann N Y Acad Sci, 962, pp. 389-401.
13. Hummel, SG, Fischer, AJ, Martin, SM, Schafer, FQ and Buettner, GR (2006) Nitric oxide as a cellular antioxidant: A little goes a long way. Free Radic Biol Med, 40, pp. 501-506.
14. Gewaltig, MT and Kojda, G. (2002) Vasoprotection by nitric oxide: Mechanisms and therapeutic potential. Cardiovasc Res, 55, pp. 250-260.
15. Faraci, FM (2006) Reactive oxygen species: Influence on cerebral vascular tone. J Appl Physiol, 100, pp. 739-743.
16. Waugh, JM, Li-Hawkins, J. and Yuksel, E. (2001) Therapeutic elastase inhibition by alpha-1-antitripsin gene transfer limits neointima formation. J Vasc Interv Radiol, 12, pp. 1203-1209.
17. Ueda, M., Mashiba, S. and Uchida, K. (2002) Evaluation of oxidized alpha-1-antitrypsin in blood as an oxidative stress marker using anti-oxidative alpha1-AT monoclonal antibody. Clin Chim Acta, 317, pp. 125-131.
18. Starosta, V. and Griese, M. (2006) Protein oxidation by chronic pulmonary diseases in children. Pediatr Pulmonol, 41, pp. 67-73.
19. Biondi, C., Pavan, B., Lunghi, L., Fiorini, S. and Vesce, F. (2005) The role and modulation of the oxidative balance in pregnancy. Curr Pharm Des, 11, pp. 2075-2089.
20. Agarwal, A., Gupta, S. and Sikka, S. (2006) The role of free radicals and antioxidants in reproduction. Curr Opin Obstet Gynecol, 18, pp. 325-332.
21. Karowicz-Bilinska, A., Marszalek, M., Kowalska-Koprek, U., Suzin, J. and Sieroszewski, P. (2004) Plasma carbonyl group concentration in pregnant women with IUGR treated by -arginine and acetylsalicylic acid. Ginekol Pol, 75, pp. 15-20.
22. Karowicz-Bilinska, A. (2004) Lipid peroxides concentration in women with intrauterine growth restriction. Ginekol Pol, 75, pp. 6-9.
23. Nishino, F., Takagi, T., Mitsuda, N., Masihiro, K., Iwata, M. and Tanizawa, O. (1990) Effect of low-dose aspirin therapy on utero-placental blood flow and malondialdehyde (MDA) as an indicator of it's therapeutic effect. Nippon Sanka Fujinka Gakkai Zasshi, 42, pp. 1641-1647.
24. Neely, MD, Amarnath, V., Weitlauf, C. and Montine, TJ (2002) Synthesis and cellular effects of an intracellularly activated analogue of 4-hydroxynonenal. Chem Res Toxicol, 15, pp. 40-47.
25. Petersen, DR and Doorn, JA (2004) Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med, 37, pp. 937-945.
26. Ishii, T., Kumazawa, S., Sakurai, T., Nakayama, T. and Uchida, K. (2006) Mass spectroscopic characterization of protein modification by malondialdehyde. Chem Res Toxicol, 19, pp. 122-129.
27. Watanabe, T., Pakala, R., Katagiri, T. and Benedict, CR (2001) Lipid peroxidation product 4-hydroxy-2-nonenal acts synergistically with serotonin in inducting vascular smooth muscle cell proliferation. Atherosclerosis, 155, pp. 37-44.
28. Aldonyte, R., Jansson, L., Ljungberg, O., Larsson, S. and Janciauskiene, S. (2004) Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerization. Histopathology, 45, pp. 587-592.
29. Blanco, LE, de Serres, FJ, Fernandes-Bustillo, E., Kassam, DA, Arbesu, D., Rodrigues, C. and Torre, JC (2005) Alpha-1-antitripsin and fibromyoalgia: New data in favour of the inflammatory hypothesis of fibromyoalgia. Med Hypotheses, 64, pp. 759-769.
30. Werler, MM, Mitchell, AA and Shapiro, S. (1989) The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med, 321, pp. 1639-1642.
31. Li, DK, Liu, L. and Odouli, R. (2003) Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: Population based cohort study. BMJ, 327, p. 368.
32. Karowicz-Bilinska, A., Suzin, J. and Sieroszewski, P. (2002) Evaluation of oxidative stress indices during treatment in pregnant women with intrauterine growth retardation. Med Sci Monit, 8, pp. CR211-CR216.
33. Karowicz-Bilinska, A., Suzin, J., Kowalska-Koprek, U. and Sieroszewski, P. (2004) Intrauterine growth restriction treatment by -arginine (and aspirine). Clinical and biochemical results. Klin Perinatol Ginekol, 40, pp. 3-7.